Which country does lvosidenib come from?

ivosidenib (Tibsovo) is the first oral small molecule targeting isocitrate dehydrogenase1 (IDH1)Mutation inhibitor. The trade name of Ivosidenib is Tibsovo. Ivosidenib is an anti-cancer drug used to treat acute myeloid leukemia (AML) and cholangiocarcinoma.

Ivonib was approved for medical use in the United States in July 2018 and in the European Union in May 2023. The U.S. Food and Drug Administration (FDA) considers it a first-in-class drug.

Patients who receivedivonib developed symptoms of differentiation syndrome, which can be fatal if left untreated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multiorgan dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. Early recognition and aggressive management of differentiation syndromes are needed to reduce the likelihood of severe illness and death. Symptoms of differentiation syndrome should be described to patients at the time of initiation of treatment and follow-up. Differentiation syndrome develops as early as 10 days and as long as 5 months after initiating treatment with another isocitrate dehydrogenase2 inhibitor. If you want to get more high-quality information, you can contact Yaodede. Yaode will do its best to learn more about high-quality overseas drugs for you.